BofA Securities raises Jazz Pharmaceuticals stock price target on Modeyso potential

BofA Securities raised its price target for Jazz Pharmaceuticals (JAZZ) to $225 from $217, maintaining a Buy rating, primarily due to the incorporation of the newly FDA-approved drug Modeyso (dordaviprone) for diffuse midline glioma into their financial model. Modeyso, the first approved treatment for this ultra-rare brain tumor, is projected to add $100 million to JAZZ's 2026 U.S. revenue, with potential peak U.S. sales exceeding $400 million if its confirmatory Phase 3 trial succeeds, highlighting significant commercial upside given the company's 92% gross margin. This positive outlook follows Jazz Pharmaceuticals' recent Q2 earnings, which saw an adjusted loss miss analyst expectations but revenue slightly exceed forecasts.

Analysis

BofA Securities has upgraded its price target on Jazz Pharmaceuticals (JAZZ) to $225 from $217, maintaining a Buy rating, a move primarily driven by the recent FDA accelerated approval of Modeyso for an ultra-rare brain tumor. This new therapy is a significant catalyst, as it is the first approved treatment for the condition. BofA's model now incorporates Modeyso, projecting it could add $100 million in 2026 U.S. revenue, with potential peak U.S. sales exceeding $400 million if the confirmatory Phase 3 ACTION trial is successful. This commercial potential is amplified by the company's robust 92% gross profit margin, suggesting new product launches can be highly accretive. However, this positive outlook is contrasted by the company's recent Q2 financial performance, where it reported an adjusted loss of $8.25 per share, missing analyst estimates, although revenue of $1.05 billion slightly beat consensus with a 2.1% year-over-year increase. An upcoming investor webcast on August 27, 2025, is a key near-term catalyst, where management is expected to provide critical details on Modeyso's pricing and ex-U.S. regulatory strategy.

Key Decisions for Investors

• Investors should weigh the significant long-term revenue potential from the newly approved drug Modeyso against the recent Q2 earnings miss, recognizing that the growth story is pipeline-dependent.
• The success of the confirmatory Phase 3 ACTION trial for Modeyso represents a critical binary event that could unlock over $400 million in peak U.S. sales, making trial updates a key factor to monitor.
• It is prudent to watch for guidance on Modeyso's pricing and international strategy during the investor webcast on August 27, 2025, as this will be crucial for validating BofA's upgraded valuation model.